Explore our drug discovery





Ex vivo analysis









High-resolution ex vivo analysis

We provide quantitative ex vivo analysis to validate biodistribution, efficacy and mechanistic findings. 

With gamma counting, autoradiography, histology and biomarker profiling in-house, we deliver clean, high-resolution data that strengthen translational confidence.



























What we deliver 

  • Gamma counting of tissues.
  • Autoradiography (alpha, beta, gamma).
  • Histology and IHC/ISH.
  • Spatial biology and mass spectrometry imaging.
  • Biomarker and phenotypic profiling.
  • Radiometabolite analysis.

One team. One workflow. One standard of quality.




Why work with us? 

  • In-house specialisms: Deep radiopharmaceutical biology expertise.
  • Translational depth: Integrated imaging, ex vivo and biomarkers.
  • Regulatory‑ready: ISO 45001 certified, licensed for alpha & beta emitters and predictive human dosimetry from pre-clinical data.
  • Integrated biology and imaging: High-resolution spatial biology.
  • Global credibility: Our environment is built for regulatory credibility, whether your next step is the FDA, EMA or MHRA.
  • Trusted by innovators: Delivering data to secure investment, progress IND‑enabling studies and move confidently toward first‑in‑human trials.

If you need ex vivo data that’s precise, quantitative and clinically meaningful, you need us.


























World-class minds for RPT discovery and development

In the complex landscape of radiochemistry and translational imaging, the difference lies in the expertise behind the science.

Our team comprises industry-leading specialists across preclinical services and radiopharmaceuticals, dedicated to bridging the gap between early discovery and clinical success.

Meet the experts who turn sophisticated data into actionable therapeutic insights.

Explore our scientific expertise

Case study: Spatial biology validation

Brief: Validate tumour uptake and mechanism using spatial biology.

We delivered: 

  • Autoradiography.
  • Mass spectrometry imaging.
  • Biomarker mapping.

Outcome: Mechanistic clarity and strengthened clinical development.


























Start your project 

Ready to accelerate your ex vivo analysis project? 

Our experts are here to support your journey from concept to clinic. Contact our team to discuss a tailored solution. 

Speak to the team, we’ll scope your project and get you moving fast. 




Expertise in radiolabelling

With gamma, beta and alpha-emitting radiometals of small molecules (e.g., FAPI, PSMA), peptides, proteins and other biologics containing chelators such as DOTA, DOTAM, Macropa, and DFO/DFO*. Experience in a variety of purification methods (e.g., ultrafiltration, SPE), QC analysis (HPLC, ITLC, gamma spectrometry), and conjugation techniques. 

Discover more






















Visualising impact in real-time

Utilising CDX and PDX models to deliver high-resolution longitudinal tumour growth inhibition (TGI) data and PK/PD analysis. 

Discover more






















Mapping the path to the target

Quantitative time-course activity analysis across 15+ organ systems using PET, SPECT and CT imaging, EBRT, US, Gamma counting and PK modelling. 

Discover more






















Ensuring safety and maximising therapeutic windows

Precise calculation of absorbed doses (Voxel/MIRD) to provide reliable preclinical-to-clinical dose extrapolation. 

Discover more






















The “See it, Treat it” advantage

Strategic pairing of diagnostic/therapeutic isotopes (e.g. 89Zr and 177Lu) to build companion imaging and patient-selection strategies. 

Discover more






















Early-stage de-risking

High-throughput screening for affinity, internalisation, and stability to identify lead candidates faster. 

Discover more






















Deep-dive tissue validation

Detailed cellular phenotyping through high-resolution autoradiography, gamma counting, and IHC correlation.

Discover more




























Explore more




We are ISO 45001 certified 

The world’s first international standard for occupational health and safety. The accreditation has been certified by Interface NRM, a UKAS and ASI–accredited certification body.











Medicines Discovery Catapult